Champlain Investment Partners LLC raised its holdings in Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 12.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,767,500 shares of the biotechnology company’s stock after acquiring an additional 191,215 shares during the quarter. Champlain Investment Partners LLC’s holdings in Veracyte were worth $72,821,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky grew its position in Veracyte by 95.6% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 24,994 shares of the biotechnology company’s stock valued at $1,161,000 after acquiring an additional 12,219 shares during the last quarter. Clough Capital Partners L P grew its position in shares of Veracyte by 12.9% during the 3rd quarter. Clough Capital Partners L P now owns 256,060 shares of the biotechnology company’s stock worth $11,894,000 after buying an additional 29,200 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Veracyte by 5.6% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,121,103 shares of the biotechnology company’s stock worth $128,589,000 after buying an additional 164,724 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Veracyte by 4.0% during the 4th quarter. ProShare Advisors LLC now owns 24,731 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 945 shares in the last quarter. Finally, FDx Advisors Inc. bought a new position in shares of Veracyte during the 4th quarter worth $244,000.
VCYT stock traded up $1.03 during trading on Thursday, hitting $16.48. 1,881,782 shares of the company traded hands, compared to its average volume of 918,261. The stock’s 50-day simple moving average is $24.45 and its 200 day simple moving average is $32.46. The company has a market cap of $1.18 billion, a PE ratio of -24.15 and a beta of 1.11. Veracyte, Inc. has a 1 year low of $14.85 and a 1 year high of $54.13.
In related news, insider Giulia C. Kennedy sold 23,003 shares of Veracyte stock in a transaction that occurred on Friday, March 4th. The stock was sold at an average price of $25.12, for a total transaction of $577,835.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.90% of the stock is currently owned by company insiders.
A number of equities analysts have recently issued reports on VCYT shares. Lake Street Capital dropped their price target on Veracyte from $95.00 to $50.00 in a research report on Tuesday, March 1st. StockNews.com started coverage on Veracyte in a research report on Thursday, March 31st. They set a “sell” rating on the stock. SVB Leerink dropped their price target on Veracyte from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 1st. Zacks Investment Research raised Veracyte from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Finally, TheStreet cut Veracyte from a “c-” rating to a “d+” rating in a research note on Tuesday, January 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Veracyte presently has an average rating of “Buy” and a consensus price target of $43.78.
About Veracyte (Get Rating)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.